C-KFAJAruna Bio
neural exosomes, blood-brain barrier, neuroregeneration
deliverydeliveringextracellular vesicle
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-KFAJ
C-KFAJC-KFAJneural exosomes, blood-brain barrier, neuroregeneration
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Aruna Bio neural exosomes, blood-brain barrier, neuroregeneration
Aruna Bio is developing a proprietary neural cell-derived exosome platform for neurological disease. Its therapeutic exosome AB126 is described as gaining access across the blood-brain barrier and acting through reduced neuro-inflammation, neuro-protection, and neuro-regeneration. The company positions AB126 for acute neuro-conditions and chronic neurodegenerative diseases.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Aruna Bio — Early mechanism · Lower middle. Derived deterministically from 7 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (4 programs at preclinical).…
Source: Deterministic